Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from the line of Joe Pantginis - Merriman Curhan Ford.
Joe Pantginis - Merriman Curhan Ford
Just a couple quick questions, obviously the focus is on a lot of your partnered products currently, I am just wondering if you add a little color on any visibility on potential data catalysts surrounding these partnered products and then the follow up question is where are you focusing mainly on your internal programs currently? Thanks a lot.
John Higgins
You bet. Joe thanks, nice to hear your voice on the call. The partnered programs, we have highlighted actually a number of clinical regulatory events this quarter. We think a very good data, particularly out of GSK for their ITP program and Wyeth for APRELA.
As far as other important events, while we do not know the timing clearly, we are interested in seeing data coming out of Bristol-Myers Phase 2 program. They have got a p38 program there in psoriasis, arthritis and so on. We have got a Phase 2 stage program partnered up with Schering there in COPD and asthma.
Both of those collaborations we brought in with our acquisition of Pharmacopeia, we are monitoring clinical trial of another public sites to try to get a sense of when the trials are fully finished and data might be out. Both partners have communicated to us that they really take a fairly kind of type approach to disclosing data but we do believe that the data from some or all of studies to be forthcoming in the next six to nine months or so.
So those are perhaps the more substantive clinical events that we are anticipating in the next several quarters. Specific to PROMACTA, as I alluded in my prepared remarks, GSK continues to make a significant investment and we have seen progress advancing PROMACTA for a number of other indications of this. I think by all accounts are believed to be the much larger indications. There is one Phase 3 ongoing for chronic liver disease. I believe ClinicalTrials.gov suggests that study to be finished or fully enrolled in 2009 and they are also running two Phase 3 trials for hepatitis.
Those are longer term studies and many more patients so we may not see data for that, for those studies for another six quarters or so but that is just a general roadmap for the more substantive news event.
- To read the full transcript on Seeking Alpha, click here »
